Predict your next investment

Venture Capital
vivocapital.com

See what CB Insights has to offer

Investments

303

Portfolio Exits

99

Funds

19

Partners & Customers

2

Service Providers

3

About Vivo Capital

Vivo Capital, fka Vivo Ventures, is a life-sciences focused venture capital firm formed in 1996 with over $650M under management. The majority of Vivo's investments are in U.S. based companies with therapeutic products in clinical development. Its current portfolio includes more than 60 private and public biotechnology companies in the areas of biopharmaceuticals, specialty pharmaceuticals, and medical devices.

Vivo Capital Headquarter Location

575 High Street Suite 201

Palo Alto, California, 94301,

United States

650-688-0818

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Vivo Capital News

Arrowhead and Vivo co-launch firm in China with $60M investment

May 3, 2022

May 3, 2022 Arrowhead Pharmaceuticals Inc. and Vivo Capital LLC have launched a joint venture named Visirna Therapeutics for RNA interference therapeutics in the greater China market. Arrowhead is the majority shareholder of the new entity, while Vivo invested $60 million in the new entity.

Vivo Capital Investments

303 Investments

Vivo Capital has made 303 investments. Their latest investment was in Visirna Therapeutics as part of their Seed VC on April 4, 2022.

CBI Logo

Vivo Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

4/25/2022

Seed VC

Visirna Therapeutics

$60M

Yes

3

3/23/2022

Series A

Ocelot Bio

$36M

Yes

5

2/7/2022

Seed VC - III

Rgenta Therapeutics

$8.91M

No

1

12/8/2021

Series A

Subscribe to see more

$99M

Subscribe to see more

10

11/29/2021

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/25/2022

3/23/2022

2/7/2022

12/8/2021

11/29/2021

Round

Seed VC

Series A

Seed VC - III

Series A

Series A

Company

Visirna Therapeutics

Ocelot Bio

Rgenta Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$60M

$36M

$8.91M

$99M

$99M

New?

Yes

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

3

5

1

10

10

Vivo Capital Portfolio Exits

99 Portfolio Exits

Vivo Capital has 99 portfolio exits. Their latest portfolio exit was AltheaDx on April 04, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

4/4/2022

Acquired

4

2/23/2022

IPO

1

11/5/2021

IPO

$99M

12

11/2/2021

Merger

Subscribe to see more

Subscribe to see more

10

10/22/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/4/2022

2/23/2022

11/5/2021

11/2/2021

10/22/2021

Exit

Acquired

IPO

IPO

Merger

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

4

1

12

10

10

Vivo Capital Acquisitions

4 Acquisitions

Vivo Capital acquired 4 companies. Their latest acquisition was Yongrenxin on June 06, 2021.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

6/6/2021

$99M

Acq - Fin

1

1/6/2021

Subscribe to see more

$99M

Subscribe to see more

10

1/1/2019

Series A

Subscribe to see more

$99M

$99M

Subscribe to see more

10

12/19/2016

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/6/2021

1/6/2021

1/1/2019

12/19/2016

Investment Stage

Series A

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

Total Funding

$99M

Note

Acq - Fin

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

Vivo Capital Fund History

19 Fund Histories

Vivo Capital has 19 funds, including Vivo Capital Fund IX.

Closing Date

Fund

Fund Type

Status

Amount

Sources

10/30/2019

Vivo Capital Fund IX

Multi-Stage Venture Capital

Closed

$1,430M

5

5/8/2019

Vivo Opportunity Co-Invest (W)

$20M

1

4/19/2019

Vivo Opportunity Co-Invest

$80M

9/4/2018

Vivo Opportunity Fund

Subscribe to see more

Subscribe to see more

$99M

10

5/26/2016

Vivo Panda Fund I

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

10/30/2019

5/8/2019

4/19/2019

9/4/2018

5/26/2016

Fund

Vivo Capital Fund IX

Vivo Opportunity Co-Invest (W)

Vivo Opportunity Co-Invest

Vivo Opportunity Fund

Vivo Panda Fund I

Fund Type

Multi-Stage Venture Capital

Subscribe to see more

Subscribe to see more

Status

Closed

Subscribe to see more

Subscribe to see more

Amount

$1,430M

$20M

$80M

$99M

$99M

Sources

5

1

10

10

Vivo Capital Partners & Customers

2 Partners and customers

Vivo Capital has 2 strategic partners and customers. Vivo Capital recently partnered with Ascendis Pharma on November 11, 2018.

Date

Type

Business Partner

Country

News Snippet

Sources

11/8/2018

Partner

Denmark

Healthcare Focused Investment Firm Ascendis Pharma Announces Formation of VISEN Pharmaceuticals to Develop and Commercialize TransCon™ Endocrinology Rare Disease Therapies in China - Vivo Capital

COPENHAGEN , Denmark -- Ascendis Pharma , a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs , today announced the formation of VISEN Pharmaceuticals , a joint venture with an investor syndicate led by Vivo Capital , to develop , manufacture and commercialize the company 's endocrinology rare disease therapies in Greater China , which includes mainland China , Hong Kong , Macau and Taiwan .

1

11/8/2018

Partner

Denmark

Subscribe to see more

Subscribe to see more

10

Date

11/8/2018

11/8/2018

Type

Partner

Partner

Business Partner

Country

Denmark

Denmark

News Snippet

Healthcare Focused Investment Firm Ascendis Pharma Announces Formation of VISEN Pharmaceuticals to Develop and Commercialize TransCon™ Endocrinology Rare Disease Therapies in China - Vivo Capital

COPENHAGEN , Denmark -- Ascendis Pharma , a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs , today announced the formation of VISEN Pharmaceuticals , a joint venture with an investor syndicate led by Vivo Capital , to develop , manufacture and commercialize the company 's endocrinology rare disease therapies in Greater China , which includes mainland China , Hong Kong , Macau and Taiwan .

Subscribe to see more

Subscribe to see more

Sources

1

10

Vivo Capital Service Providers

3 Service Providers

Vivo Capital has 3 service provider relationships

Service Provider

Associated Rounds

Provider Type

Service Type

Acq - Fin

Counsel

General Counsel

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Service Provider

Subscribe to see more

Subscribe to see more

Associated Rounds

Acq - Fin

Subscribe to see more

Provider Type

Counsel

Subscribe to see more

Subscribe to see more

Service Type

General Counsel

Subscribe to see more

Partnership data by VentureSource

Vivo Capital Team

17 Team Members

Vivo Capital has 17 team members, including current Managing Partner, Edgar G. Engleman.

Name

Work History

Title

Status

Edgar G. Engleman

Managing Partner

Current

Edgar G Englemen

Managing Partner

Current

Shan Fu

Managing Partner

Current

Frank Kung

Managing Partner

Current

Chen Yu

Managing Partner

Current

Name

Edgar G. Engleman

Edgar G Englemen

Shan Fu

Frank Kung

Chen Yu

Work History

Title

Managing Partner

Managing Partner

Managing Partner

Managing Partner

Managing Partner

Status

Current

Current

Current

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.